About Ambrx
Ambrx is a Healthcare company based in San Diego (United States) founded in 2003, and was acquired by Johnson & Johnson in January 2024. Antibody-drug conjugates are developed for cancers and metabolic disorders. Ambrx has raised $345.9 million across 6 funding rounds from investors including Fidelity Investments, Johnson & Johnson and Merck. The company has 79 employees. Ambrx offers products and services including ARX788, ARX517, and ARX305. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Ambrx, Inc. Its competitors include Denali Therapeutics, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.
Company details
Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer
- Annual Revenue$7.4 M (USD)-1as on Dec 31, 2022
- Net Profit-$78 M (USD)-15as on Dec 31, 2022
- EBITDA-$76.4 M (USD)-19as on Dec 31, 2022
- Total Equity Funding$345.9M (USD)
in 6 rounds
- Latest Funding Round$200M (USD), Series E
Nov 2020
- InvestorsFidelity Investments
& 22 more
- Employee Count79
- Acquired by
Products & Services of Ambrx
Ambrx offers a comprehensive portfolio of products and services, including ARX788, ARX517, and ARX305.
Targets cancer with stable, site-specific conjugation for effective treatment
Focuses on advanced prostate cancer through enhanced protein engineering
Develops conjugates for potential oncology applications in clinical settings
Funding Insights of Ambrx
Ambrx has successfully raised a total of $345.9M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $200 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $345.9M
- Total Rounds 6
- Last Round Series E — $200M
- First Round $12.5M
(Oct 2003)
- Investors Count 20
All 6 funding rounds of Ambrx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $200M | Series E | – | Fidelity Investments | |
| Aug 2016 | $45M | Series E | – | Apricot Capital | |
| Mar 2009 | $10M | Series D | – | Merck | |
| Jul 2006 | $55M | Series C | – | Apposite Capital, Glynn Capital | |
| Apr 2005 | $23.4M | Series B | – | – | |
| Oct 2003 | $12.5M | Series A | – | – |
23 investors in total: 23 institutional.
Investors in Ambrx
Ambrx has secured backing from 23 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Johnson & Johnson and Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
| sinopharmcapital.com | ||||
| apricot-capital.com | ||||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
| cmea.com | ||||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Tavistock Group is engaged in global diversified investments. | tavistock.com | |||
Growth capital is provided by Aravis for Swiss high-tech companies. | aravis.ch | Switzerland | ||
Early-stage tech and life-sciences firms are funded across the US. | maverickventures.com | San Francisco, United States |
Investor details for Ambrx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ambrx
28 people are tracked at Ambrx (15 in leadership, 6 in board & advisors, 7 in team); the tracked headcount is 79.
| Name | Role | Group |
|---|---|---|
Mark Janis | Vice President, Corporate Controller | Leadership |
Ying Sun | Associate Director Of Chemistry | Leadership |
Douglas Pierce | Vice President, SEC Reporting And Technical Accounting | Leadership |
Sandra Aung | Chief Clinical Officer | Leadership |
Thuy le | Associate Director Of Clinical Operations | Leadership |
Douglas Greene | Vice President, Clinical Pharmacology | Leadership |
Colin Hessel | Executive Vice President, Development Operations | Leadership |
Lilly Vukov | Associate Director Of Operations | Leadership |
Sigeng Chen | Director | Leadership |
Ricardo Burgos | Senior Director Quality | Leadership |
Mingchao Kang | Group Lead, Head Of Technology Platform | Leadership |
Darryl Z. L'Heureux | Director, Clinical Science And Medical Affairs | Leadership |
Johanna Acosta | Senior Director, Talent Acquisition & Development | Leadership |
Sunita Hack | Senior Director, Clinical And Program Strategy | Leadership |
Mysore Ramprasad | Vice President, Pharmaceutical & Analytical Development At Ambrx, A Johnson & Johnson Co. | Leadership |
Jakob Dupont | Scientific Advisor | Board & advisors |
Peter Schultz | Scientific Advisor | Board & advisors |
Paul Maier | Board Member | Board & advisors |
Stuart Lutzker | Scientific Advisor | Board & advisors |
Stephen Glover | Chair | Board & advisors |
8 more people are available in the full profile.
Complete people profiles for Ambrx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ambrx
6 dated milestones of Ambrx across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Ambrx is founded.
- Funding First funding round of $12.5M.
- Exit Acquired by Fosun.
- Funding Latest funding round, Series E, of $200.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Johnson & Johnson.
Competitors of Ambrx
Ambrx has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, C4 Therapeutics and Erasca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Ambrx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ambrx
The website of Ambrx (ambrx.com) receives about 1.7K visits a month and ranks #3,844,291 among all websites worldwide, #4,904 in Biotechnology and Pharmaceuticals.
- Monthly visits1.7K
▼ 61.2% vs previous month
- Unique visitors1.8K
per month
- Global rank#3,844,291
among all websites
- Category rank#4,904
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit2.2
- Average visit1 min 25 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Ambrx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| btsresearch.com | 100% | View details | |||
| ajibio-pharma.com | 100% | 4.7K | #3,787,378 | View details | |
| aspenneuroscience.com | 98% | 6.1K | #2,537,044 | View details | |
| bioagilytix.com | 96% | 41.6K | #919,146 | View details | |
| crinetics.com | 94% | 21.7K | #1,355,406 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Ambrx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Ambrx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ambrx
Complete news archive for Ambrx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ambrx
Ambrx was founded in 2003.
Ambrx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ambrx is a funded company, having raised a total of $345.9M across 6 funding rounds to date. The company's 1st funding round was a Series A of $12.5M, raised on Oct 2003.
Ambrx has 79 employees.
Annual revenue of Ambrx is $7.4M as on Dec 31, 2022.
Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer.
Ambrx's top competitors include C4 Therapeutics, Erasca and Denali Therapeutics.
Ambrx offers ARX788, ARX517, and ARX305.
Ambrx has 23 investors. Key investors include Fidelity Investments, Johnson & Johnson, Merck, WuXi AppTec, and BlackRock.
Ambrx operates through Ambrx, Inc..
Yes. Ambrx was acquired by Fosun in May 2015.